{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:16:42Z","timestamp":1788585402509,"version":"build-2803163510"},"reference-count":20,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7883\/yoken.jjid.2025.245","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T22:10:16Z","timestamp":1788127816000},"source":"Crossref","is-referenced-by-count":0,"title":["Superior in vitro Activity of Cefepime\u2013Enmetazobactam Over Ceftazidime\u2013Avibactam and Piperacillin\u2013Tazobactam Against 3&lt;sup&gt;rd&lt;\/sup&gt; Generation cephalosporin resistant Enterobacterales"],"prefix":"10.7883","author":[{"given":"Prabhav","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Department of Microbiology, Maulana Azad Medical College, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Maulana Azad Medical College, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anugula","family":"Amritha","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Maulana Azad Medical College, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Kaim","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Maulana Azad Medical College, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. O&apos;Connor A, Lopez MJ, Patel P, et al. Cefepime. (Updated 2024 Feb 28). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542232\/. Accessed November 5, 2025."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bhowmick T, Canton R, Pea F, et al. Cefepime-enmetazobactam: first approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales. Future Microbiol. 2025 Mar;20(4):277-286.","DOI":"10.1080\/17460913.2025.2468112"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Husna A, Rahman MM, Badruzzaman ATM, et al. Extended-Spectrum \u03b2-Lactamases (ESBL): Challenges and Opportunities. Biomedicines. 2023 Oct 30;11(11):2937.","DOI":"10.3390\/biomedicines11112937"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Darlow CA, Hope W, Dubey V. Cefepime\/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation. Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):115-123.","DOI":"10.1080\/17425255.2024.2427310"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Keam SJ. Cefepime\/Enmetazobactam: First Approval. Drugs. 2024 Jun;84(6):737-744.","DOI":"10.1007\/s40265-024-02035-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kaye KS, Belley A, Barth P, et al. Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA. 2022;328(13):1304-1314.","DOI":"10.1001\/jama.2022.17034"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lanier C, Melton T, Covert K. Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam\/Beta-Lactamase Inhibitor. Ann Pharmacother. 2025;59(6):570-576.","DOI":"10.1177\/10600280241279904"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ramaraj A, Nivasini NT, Balaji V, et al. (2025). Cefepime-Enmetazobactam: a novel \u03b2-Lactam\/\u03b2-Lactamase inhibitor combination for complicated urinary tract infections. Int J Basic Clin Pharmacol. 2025;14(4):590\u2013596.","DOI":"10.18203\/2319-2003.ijbcp20251745"},{"key":"9","unstructured":"9. Hannah Clarke. FDA approves cefepime\/enmetazobactam for complicated UTI. Urology Times Journal. 2024; 52. Available at: https:\/\/www.urologytimes.com\/view\/fda-approves-cefepime-enmetazobactam-for-complicated-uti. Accessed November 5, 2025."},{"key":"10","unstructured":"10. National Centre for Disease Control. Annual Report National Antimicrobial Surveillance Network (NARS-Net), Reporting period January \u2013 December 2023. Available at: https:\/\/ncdc.mohfw.gov.in\/wp-content\/uploads\/2024\/09\/Final-Annual-Report-2023-06_08_2024.pdf. Accessed November 5, 2025."},{"key":"11","unstructured":"11. Indian Council Of Medical Research. Antimicrobial surveillance and research network annual report 2023-2024. Available at: https:\/\/www.icmr.gov.in\/icmrobject\/uploads\/Documents\/1725536060_annual_report_2023.pdf. Accessed November 5, 2025."},{"key":"12","unstructured":"12. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 35th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2025."},{"key":"13","unstructured":"13. CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data. 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute; 2022."},{"key":"14","unstructured":"14. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, 2025. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf. Accessed November 5, 2025."},{"key":"15","unstructured":"15. US Food &amp; Drugs Administration. Cefepime and Enmetazobactam Injection. Available at https:\/\/www.fda.gov\/drugs\/development-resources\/cefepime-and-enmetazobactam-injection. Accessed November 5, 2025."},{"key":"16","unstructured":"16. Indian Council Of Medical Research. Guidance on Diagnosis &amp; Management of Carbapenem Resistant Gram-negative Infections. Available at: https:\/\/www.icmr.gov.in\/icmrobject\/custom_data\/pdf\/resource-guidelines\/Diagnosis_and_management_of_CROs.pdf. Accessed November 5, 2025."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Siddaramappa S, Pullela K, Thimmappa B, et al. Characterization of <i>bla<\/i><sub>CTX-M<\/sub> sequences of Indian origin and thirteen uropathogenic <i>E. coli<\/i> isolates resistant to multiple antibiotics. BMC Res Notes. 2018;11(1):630.","DOI":"10.1186\/s13104-018-3735-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Morrissey I, Hawser S, Kothari N, et al. Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates. J Glob Antimicrob Resist. 2024;38:71-82.","DOI":"10.1016\/j.jgar.2024.04.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hidalgo-Tenorio C, Bou G, Oliver A et al. The Challenge of Treating Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Gram-Negative Bacteria: A Narrative Review. Drugs. 2024;84:1519\u20131539 (2024).","DOI":"10.1007\/s40265-024-02102-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. R\u00e9my A. Bonnin, Katy Jeannot, et al. In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. Clin Microbiol Infect. 2025;31(2):240-249.","DOI":"10.1016\/j.cmi.2024.09.031"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.245\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:44:53Z","timestamp":1788583493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.245\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2025.245","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"JJID.2025.245"}}